The power of remote patient monitoring
There is limited data comparing remote post-discharge patient treatment to that of standard in-person care, but a new clinical trial has done exactly that.
This multicenter randomized control trial measured safety events, medication adjustment and left ventricular reverse remodeling outcomes. The subjects were low-risk patients with acute myocardial infarction treated for 6 months after discharge by a centralized nurse practitioner–led telehealth program compared with standard in-person care by a cardiologist. There were no differences in achieved medication doses or indices of left ventricular remodeling.
This clinical trial set out to answer an important question for healthcare in a COVID and post-COVID landscape:
“Is remote post-discharge treatment of low-risk patients with acute myocardial infarction by a centralized nurse clinician team under physician supervision feasible and safe?”
The answer is: Absolutely. In fact, it’s both safe and effective.
Researchers now want to conduct a similar clinical trial with higher-risk patients, in an effort to further test the capabilities of remote intensive patient management and care. Read this impactful new study here:
The future is here:
cliexa-PULSE Home Health Monitoring Platform co-developed by cliexa and American College of Cardiology
“Imagine the ability to effectively capture RPM in the cardiology’s major disease states – HTN, CHF, CAD, and AFib in an easy-to-use-tool without all the data overload: Enter cliexa!” Dr. Andrew M. Freeman, MD – Director of Clinical Cardiology and Operations Director Cardiovascular Prevention & Wellness at National Jewish Health
Through the ACC Innovation Program with our partners at the American College of Cardiology (ACC), we have developed one of our latest modules, cliexa-PULSE to digitally transform and ultimately optimize cardiovascular care and outcomes. cliexa-PULSE is a mobile application designed for patients to track their symptoms, medications, episodes, complications and daily activity to manage Atrial Fibrillation providing real-time data to their clinicians. The expansion of cliexa-PULSE in 2021 will provide treatment tracking tools for patients with Hypertension, Congestive Heart Failure and Coronary Artery Disease, as well as launching a population health module. cliexa-PULSE is the ideal mobile app for clinicians to fully leverage patient-reported data, improving treatment decision-making and the overall patient experience. Learn more about cliexa-PULSE HERE